Arena third quarter net loss increases to $36.
Arena third quarter net loss increases to $36.3 million Arena Pharmaceuticals, Inc. today reported monetary results for the 3rd quarter ended September 30, 2010 doctor . Arena also reported earlier today top-line outcomes from its lorcaserin Phase 3 BLOOM-DM trial. We believe the BLOOM-DM top-line outcomes provide extra support for lorcaserin’s benefit-to-risk profile, said Jack Lief, Arena’s President and Chief Executive Officer. We remain focused on addressing the recommendations outlined by the FDA in the entire response letter for lorcaserin. Arena reported a net reduction in the third one fourth of 2010 of $36.3 million, or $0.31 per share, in comparison to a net loss in the third quarter of 2009 of $34.8 million, or $0.38 per talk about, and a net reduction in the first nine months of 2010 of $96.3 million, or $0.91 per share, in comparison to a net reduction in the initial nine months of 2009 of $123.4 million, or $1.51 per share.